Interleukin-17F Antibodies

Interleukin-17F (IL17F)

Ligand for IL17RA and IL17RC (PubMed:17911633).

The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC (PubMed:18684971).

Involved in stimulating the production of other cytokines such as IL6, IL8 and CSF2, and in regulation of cartilage matrix turnover (PubMed:11591732, PubMed:11591768, PubMed:11574464). Also involved in stimulating the proliferation of peripheral blood mononuclear cells and T-cells and in inhibition of angiogenesis (PubMed:11591732).

Gene Information

Human
Gene Name:	IL17F
Uniprot:	Q96PD4
Entrez:	112744

Family

Belongs to:
IL-17 family

Alternative Names

Cytokine ML-1; IL17F; IL-17F; IL-17Finterleukin-17F; IL24; IL-24; interleukin 17F; Interleukin-24; ML-1; ML1interleukin-24

Molecular Weight

Mass (kDA):
18.045 kDA

Genomic Context

Human
Location:	6p12.2
Sequence:	6; NC_000006.12 (52236681..52245689, complement)

Tissue Specificity

Expressed in activated, but not resting, CD4+ T-cells and activated monocytes.

Subcellular Localizations

Secreted.

Diseases

• Inflammation
• Autoimmune Reaction
• Autoimmune Diseases
• Asthma
• Neoplasms
• Ulcer
• Malignant Neoplasms
• Arthritis
• Colitis
• Autoimmunity
• Ulcerative Colitis
• Rheumatoid Arthritis
• Crohn Disease

• Encephalomyelitis
• Experimental Autoimmune Encephalomyelitis
• Intestinal Diseases
• Infective Disorder
• Inflammatory Bowel Diseases
• Tumor Angiogenesis
• Sclerosis

Pathways

• Pathogenesis
• Secretion
• Cell Differentiation
• Immune Response
• Cytokine Production
• Angiogenesis
• Chemokine Production
• Cell Activation
• T Cell Activation
• Cell Cycle
• Intracellular Signal Transduction
• Demethylation
• Methylation

• Rna Interference
• Cell Migration
• Dna Demethylation
• Complement Activation
• Cell Fate Determination
• Mucus Secretion
• Inflammatory Response

PTMs

• Methylation
• Phosphorylation

• Demethylation
• Acetylation

Research Areas

• Cytokine Research

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/IL17F

Best Uses Of The IL17F Marker

The IL17F Marker is a highly specific recombinant human IL-17 antibody that binds to the heterodimer complex formed by IL17RC and RA. It can be used in a variety of applications, including in vitro diagnostics and in cell biology research. It has also been shown to have a high affinity and specificity, making it an excellent choice for research in a variety of fields.

IL17F Marker is a recombinant human IL-17

IL-17A/F is an important cytokine for the immune system. Infection with Helicobacter pylori can cause an overactive inflammatory response resulting in Th2 and Th27 cell activation. In turn, this inflammatory response can lead to gastric cancer. However, it may be necessary to regulate the activity of IL-17RA, which recruits neutrophils. Human epithelial cell lines were used to explore the differential role of IL-17A and IL-17F.

The IL-17F Marker is a recombinational human IL-17 gene. It is used to monitor the activity of IL-17 receptors on different WBC populations. IL-17A/F stimulation of AGS and Cd4creIl17ra/f mice upregulates the expression of polymeric Ig receptor gene (PIGR) in these cells.

IL-17F Blockade results in significant reductions in airway inflammation and infiltration of neutrophils. Neutrophil recruitment and airway vascular remodelling in mice treated with IL-17F monoclonal antibody reduced significantly. Antibodies against IL-17F also inhibit the recruitment of airway eosinophils. The monoclonal antibody neutralises IL-17F, reducing the Th27-related response and airway inflammation.

The IL-17 family includes seven structurally similar cytokines, including IL-17A/F. IL-17A and IL-17F signal through the IL-17RA/RC multimeric receptor. The IL-17A/IL-17F axis has been associated with an increased immune response. However, their roles have been unclear. IL-17F and IL-17A/F are both important cytokines, with a variety of functions.

The IL-17A/IL-17F molecule are closely related, and are bioactive homodimers. The three forms of IL-17A/IL-17F signal through the same receptor complex. IL-17A and IL-17F share more than four4% sequence homology. Both are expressed by T-cells and monocytes. Further, both types of IL-17A/IL-17F have a role in the recruitment of neutrophils and inflammatory responses.

The IL-17A/F marker is produced in a laboratory via fermentation. This recombinant human IL-17A/F antibody has a neutralizing effect on the IL-17F secretion of a mouse embryonic fibroblast cell line. The monoclonal antibody neutralizes the stimulatory effect of the IL-17F-stimulated IL-6 in the cell lines.

IL17F Marker is a vector

The IL17F marker is a novel vector in Boster Bio's proprietary IL17F gene therapy. It is a proinflammatory cytokine that activates T-lymphocytes and promotes maturation of CD34-positive precursor cells into neutrophils. The gene encoding interleukin 17A encodes a type I membrane glycoprotein that binds with a low affinity to interleukin-17A. The IL17A receptor is expressed in many tissues and cell types, including the liver. The IL17A pathway is a key area of research for inflammatory diseases, including liver cirrhosis and alcoholic liver disease.

The IL17F Marker is produced in the Sf9 Baculovirus cell line using proprietary chromatographic techniques. It is a single chain polypeptide with 142 amino acids and a molecular mass of 16kDa. Its function is to regulate the turnover of cartilage matrix, enhance T cell cytotoxicity, and contribute to the clearance of viral infections. IL17F also stimulates the production of B-1a B cells, which provide virus-specific IgM antibodies.

Human IL-17F is expressed in two types of cells: neuroblastoma and glioma. The receptors of both IL-17RA and IL-17C have been identified in the brain. The IL-17 receptor is also expressed on Schwann cells and neurites. This receptor is neurotropic in a range of neuronal cells, including primary HSNs. In Caenorhabditis elegans, the IL-17 pathway modulates sensory neurons.

Activated HSCs were cultured on days one, two, and five following their isolation. Activated HSCs expressed a fluorescent protein known as desmin. Immunocytochemical staining for a-smooth muscle actin confirmed that the cells were activated HSCs. The purity of activated HSCs reached 98%. There is no evidence of any adverse effects from the IL-17F Marker.

IL17F Marker is a ligand for the heterodimer complex formed by IL17RA and IL17RC

IL-17A and -F receptors are essential for converting IL-17 into a signaling molecule. Each ligand has a biased affinity for its hetero-receptor, and each is capable of binding to the other receptor in a heterodimer. IL-17A binds to IL-17RA with approximately ten times greater affinity than IL-17F, and the IL-17F/IL-17RA heterodimer complex is capable of binding to both receptors with similar affinity.

IL-17A and -R is a key player in inflammatory diseases. This cytokine is implicated in promoting bone erosion, particularly in rheumatoid arthritis (RA). It promotes cartilage breakdown and inflammation in the joints. It also induces expression of chemokines in the synovium, allowing neutrophils to invade the rheumatoid synovium.

The IL17F Marker is a synthetic protein that functions as a ligand for the heterodomer complex between IL17RA and IL17RC. It is produced by the immune system and regulates cell-mediated immunity. Interleukin-17 is a powerful proinflammatory cytokine that stimulates the production of T cells. Several studies have demonstrated that it correlates with disease activity in rheumatoid arthritis and osteoarthritis.

IL-17RA and IL17F receptors have unique features. Both IL-17F and IL-17RA heterodimers bind IL-17A, which is a potent proinflammatory cytokine. When IL-17A binds to the IL-17RA homodimer, it recruits a ligand called Act1. This signaling molecule activates TRAF6 and other transcription factors, resulting in the induction of various cytokines and chemokines.

IL-17RA and IL-17RC mRNA expression was significantly higher in BP patients than in control subjects. IF staining confirmed the overexpression of IL-17RA receptors in BP patients. Similarly, longitudinal variation of IL-17RA and IL17F receptors was assessed in BP patients with relapse and ongoing remission. Interestingly, the baseline clinical characteristics of BP patients with relapse were similar to those of those with ongoing remission.

IL-17RA and IL17RC levels were increased in BP patients with mild to moderate disease, but not in controls. Serum levels of IL-17B were significantly higher in patients with BP than in controls. However, the levels of IL-17C were not significantly different between patients with BP and control subjects.

IL17F Marker is a high-affinity primary antibody

The IL17F Marker is a highly specific monoclonal antibody for the detection of IL-17F protein in a variety of biological samples. This high-affinity protein has been validated on immunohistochemistry, Western Blotting, and ELISA. Boster Bio IL17F Marker is a high-affinity primary antibody for the detection of this protein.

The IL17A gene encodes a protein known as interleukin-17. Activated T cells produce this protein. It regulates NF-kappaB activity and mitogen-activated protein kinases. In addition, it regulates the expression of IL6 and nitric oxide in various cell types. Interleukin-17A is a known factor in inflammatory diseases such as psoriasis and multiple sclerosis. This high-affinity monoclonal antibody is highly specific and has a long-term potency.

The mAb was purified by DEAE-cellulose ion exchange chromatography. It interacted with human IgM with high affinity and specificity, 3.5 x 10(9)M(-1). Immunoblotting and competitive ELISA confirmed that the monoclonal antibody has a conformational epitope on the mu chain.

This monoclonal antibody recognizes human coagulating factor VII (IFX). It is also an excellent choice for the detection of IL17F. Its reactivity with factor VII from other species is minimal, minimizing the risk of bovine FVII contamination. It is also compatible with the Boster Bio IL17F Marker as a high-affinity primary antibody.

IL17F is a glycoprotein that binds to IL4Ralpha, IL-17F receptors and IL-4Ralpha. These proteins are expressed on several types of cell types in the airways, and stimulate the production of mucus and chemokines. Antibodies that bind to these proteins block the recruitment of IL-4Ralpha.

Boster Bio IL17F Marker, a high-affinity primary antibody for IL17F, targets Tfh cells. Tfh cells are CD4+ T cells that help the immune system to fight infection. It promotes neutrophil recruitment to infection sites, killing extracellular bacterial and fungal antigens, and enhancing germinal center formation. It also promotes B cell somatic hypermutation and selection towards plasma cells.

Immunogenicity to IL17F is known to induce a strong T-cell response to HIV. In turn, this protein can be used to develop vaccines that target T cells specifically. This is a unique and innovative approach to the development of vaccines for HIV-1 infection. These antibodies have the potential to be used to detect HIV-1 proteins, and are useful in many research settings.